Sigilon Therapeutics, Inc. Profile Avatar - Palmy Investing

Sigilon Therapeutics, Inc.

Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with m…

Biotechnology
US, Cambridge [HQ]

Cash Flow Statements

Loading...
End of SGTX's Analysis
CIK: 1821323 CUSIP: 82657L107 ISIN: US82657L1070 LEI: - UEI: -
Secondary Listings
SGTX has no secondary listings inside our databases.